Circulating irisin levels in functional hypothalamic amenorrhea: a new bone damage index? A pilot study

Area of Science:

• Endocrinology
• Bone Metabolism
• Sports Medicine

Background:

• Functional hypothalamic amenorrhea (FHA) is linked to metabolic alterations and potential bone damage due to energy deficits.
• Current methods for detecting osteopenia, such as DXA scans, identify bone loss only after it has occurred.
• Irisin, a myokine, promotes osteoblast differentiation and may be associated with bone health.

Purpose of the Study:

• To investigate irisin levels in patients with FHA.
• To determine the correlation between irisin levels and bone density parameters in FHA patients.

Main Methods:

• A study involving 32 FHA patients and 19 healthy controls.
• Clinical and laboratory evaluations were performed on all participants.
• Measurements included serum irisin levels, body mass index (BMI), and bone mineral density (BMD).

Main Results:

• FHA patients exhibited significantly lower irisin levels and BMI compared to controls.
• Total body BMD was significantly reduced in the FHA group, though osteopenia was not yet evident.
• Lower irisin levels were associated with reduced BMD parameters in FHA patients.

Conclusions:

• Reduced irisin levels in FHA patients are associated with decreased BMD, potentially preceding osteopenia.
• Irisin may serve as a predictive marker for bone density changes and an indicator of energy deficit in FHA.
• Further research with larger populations is needed to validate irisin as a screening tool for bone deprivation in FHA.